Peter Lynch fit · Growth at a reasonable price (GARP)
Is Jazz Pharmaceuticals plc (JAZZ) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria - growth too low or price too high.
34/100
FNot a fit
2/6 criteria passed
+2 sector-quality lift. Top-quintile within its sector on 1 of 5 quality metrics. Raw pillar score 32 → lifted to 34 before grade derivation.
Peter Lynch's Criteria, Applied to JAZZ
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
8.4%
Net margin > 0
0.7%
Manageable debt (D/E < 1)
1.2x
Positive free cash flow
Yes
How JAZZ Scores on Other Strategies
Live Financial Snapshot
Market cap
$14.6B
P/E (TTM)
501.8x
ROIC (TTM)
-0.62%
Gross margin
84.12%
Other Peter Lynch fit reports
Frequently Asked Questions
What is JAZZ's Peter Lynch fit score?
JAZZ scores 34/100 on our Peter Lynch fit engine - grade F. Does not fit Lynch's GARP criteria - growth too low or price too high.
Does Peter Lynch actually own JAZZ?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends JAZZ.
How often is this score updated?
JAZZ's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends JAZZ.